Sales flat lining, export strategy struggling, PBT down on pcp, OCF negative AGAIN!!!, Net Debt increased to $13m from $10m at June year end. Given seasonal impact 2H NPAT likely to be ~$4m, giving FY17F NPAT of ~$9m vs Mkt Cap of $146m = PE of 16x. Seems expensive given its sales growth, cost growth and Cash Flow issues.
- Forums
- ASX - By Stock
- CZZ
- Ann: Half Year Broker Presentation - February 2017
Ann: Half Year Broker Presentation - February 2017, page-2
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CZZ (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online